DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
DiaMedica Therapeutics rescheduled its key opinion leader webinar on DM199 for fetal growth restriction from October 23 to Tuesday, November 24, 2026, at 8:00am ET. The new date allows the company to add preliminary interim topline results from the second cohort of the investigator-sponsored Phase 2 early-onset FGR trial to the presentation, alongside first-cohort results. The panel will feature professors Cluver, Tong, Walker and Shennan, with Dr. Cluver — the trial's Principal Investigator — presenting safety, tolerability and cohort results from the Tygerberg Hospital study in South Africa.
Key figures
- Dosing levels
- 5, 10 and up to 15 µg/kg
- Fgr prevalence
- an estimated 10% of pregnancies worldwide
- Trial subjects
- up to 30 early-onset FGR subjects
- Participants enrolled
- first two cohorts of 12 participants
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.